Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America

Most prostate cancer patients who undergo androgen-deprivation therapy or orchiectomy will eventually develop castration-resistant prostate cancer (CRPC), often preceded by a nonmetastatic CRPC state known as M0CRPC. The recent development of second-generation antiandrogens provides clinicians with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ray Manneh, Ricardo Brugés, Jose Jaime Correa, Julián Rojas, Daniel Rojas, Nicolás Villareal
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Diseases of the genitourinary system. Urology RC870-923 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/28ebbd61bfad401985badd8042584f0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:28ebbd61bfad401985badd8042584f0b
record_format	dspace
spelling	oai:doaj.org-article:28ebbd61bfad401985badd8042584f0b2021-11-22T01:10:58ZManagement of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America2090-312X10.1155/2021/3334333https://doaj.org/article/28ebbd61bfad401985badd8042584f0b2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/3334333https://doaj.org/toc/2090-312XMost prostate cancer patients who undergo androgen-deprivation therapy or orchiectomy will eventually develop castration-resistant prostate cancer (CRPC), often preceded by a nonmetastatic CRPC state known as M0CRPC. The recent development of second-generation antiandrogens provides clinicians with efficacious and safe treatments for M0CRPC. However, the complexity of these patients, who typically have to deal with underlying comorbidities and polypharmacy, often challenges therapeutic decisions in this setting. The recent development of novel imaging techniques also provides clinicians with tools for detecting metastases with high sensitivity and specificity. However, the lack of evidence on the early detection of metastases and the corresponding impact on therapeutic decisions makes these techniques a double-edged sword that must be managed appropriately. Here, we present the expert view of the rapidly evolving concept of M0CRPC and provide recommendations for the identification of these patients, the appropriate use of the emerging imaging modalities, and patients’ management, particularly considering their clinical complexity and the recent development of next-generation antiandrogens.Ray MannehRicardo BrugésJose Jaime CorreaJulián RojasDaniel RojasNicolás VillarealHindawi LimitedarticleDiseases of the genitourinary system. UrologyRC870-923Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENProstate Cancer, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the genitourinary system. Urology RC870-923 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Diseases of the genitourinary system. Urology RC870-923 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ray Manneh Ricardo Brugés Jose Jaime Correa Julián Rojas Daniel Rojas Nicolás Villareal Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America
description	Most prostate cancer patients who undergo androgen-deprivation therapy or orchiectomy will eventually develop castration-resistant prostate cancer (CRPC), often preceded by a nonmetastatic CRPC state known as M0CRPC. The recent development of second-generation antiandrogens provides clinicians with efficacious and safe treatments for M0CRPC. However, the complexity of these patients, who typically have to deal with underlying comorbidities and polypharmacy, often challenges therapeutic decisions in this setting. The recent development of novel imaging techniques also provides clinicians with tools for detecting metastases with high sensitivity and specificity. However, the lack of evidence on the early detection of metastases and the corresponding impact on therapeutic decisions makes these techniques a double-edged sword that must be managed appropriately. Here, we present the expert view of the rapidly evolving concept of M0CRPC and provide recommendations for the identification of these patients, the appropriate use of the emerging imaging modalities, and patients’ management, particularly considering their clinical complexity and the recent development of next-generation antiandrogens.
format	article
author	Ray Manneh Ricardo Brugés Jose Jaime Correa Julián Rojas Daniel Rojas Nicolás Villareal
author_facet	Ray Manneh Ricardo Brugés Jose Jaime Correa Julián Rojas Daniel Rojas Nicolás Villareal
author_sort	Ray Manneh
title	Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America
title_short	Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America
title_full	Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America
title_fullStr	Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America
title_full_unstemmed	Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America
title_sort	management of patients with nonmetastatic castration-resistant prostate cancer: recommendations of a multidisciplinary panel of experts from south america
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/28ebbd61bfad401985badd8042584f0b
work_keys_str_mv	AT raymanneh managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT ricardobruges managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT josejaimecorrea managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT julianrojas managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT danielrojas managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica AT nicolasvillareal managementofpatientswithnonmetastaticcastrationresistantprostatecancerrecommendationsofamultidisciplinarypanelofexpertsfromsouthamerica
_version_	1718418329153044480

Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America

Ejemplares similares